Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck Drops One Migraine Program, Continues Another | Contract Pharma

What are you searching for?

Sign in

Merck Drops One Migraine Program, Continues Another

Merck has updated the status of the clinical development programs for MK-0974 (telcagepant) and MK-3207, the company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the treatment of acute migraine.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck has updated the status of the clinical development programs for MK-0974 (telcagepant) and MK-3207, the company’s investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the treatment of acute migraine.

Merck is discontinuing the clinical development program for MK-3207. While efficacy was demonstrated in a Phase II study with the drug, some subjects in extended Phase I pharmacology studies were found to have experienced delayed, asymptomatic liver test abnormalities, generally following discontinuation of drug administration.

For telcagepant, which is currently in Phase III development, the company is reviewing available clinical data in preparation for discussions with regulatory agencies planned for later this year.

“Merck believes that the blocking of CGRP receptors remains an exciting pathway to address the underlying pathophysiology of migraine,” said David Michelson, M.D., vice president of clinical neurosciences, Merck Research Laboratories. “We are continuing our efforts to offer patients a new treatment approach.”

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters